| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,320,000 |
| Market
Cap: |
8.08(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$80.05 - $182.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 8.7 |
|
| Guru Rank Number : 1068 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,575 |
1,575 |
1,575 |
| Total Buy Value |
$0 |
$200,466 |
$200,466 |
$200,466 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
281,489 |
564,821 |
692,008 |
826,155 |
| Total Sell Value |
$39,671,221 |
$73,367,257 |
$87,065,769 |
$97,633,440 |
| Total People Sold |
2 |
4 |
7 |
7 |
| Total Sell Transactions |
7 |
22 |
35 |
43 |
| End Date |
2025-10-09 |
2025-07-08 |
2025-01-07 |
2024-01-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Tabuteau Herriot |
Chief Executive Officer |
|
2026-01-07 |
4 |
AS |
$170.38 |
$5,326,249 |
D/D |
(31,261) |
7,229 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2026-01-07 |
4 |
OE |
$8.02 |
$250,713 |
D/D |
31,261 |
38,490 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2026-01-06 |
4 |
AS |
$172.33 |
$5,075,119 |
D/D |
(29,450) |
7,229 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2026-01-06 |
4 |
OE |
$8.02 |
$236,189 |
D/D |
29,450 |
36,679 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2026-01-05 |
4 |
AS |
$171.28 |
$13,480,250 |
D/D |
(78,703) |
7,229 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2026-01-05 |
4 |
OE |
$8.02 |
$631,198 |
D/D |
78,703 |
85,932 |
|
- |
|
Saad Mark E |
|
|
2025-12-31 |
4 |
AS |
$165.18 |
$6,206,969 |
D/D |
(37,577) |
10,002 |
|
-2% |
|
Saad Mark E |
|
|
2025-12-31 |
4 |
OE |
$4.95 |
$205,135 |
D/D |
37,577 |
41,348 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-12-04 |
4 |
AS |
$148.18 |
$1,564,484 |
D/D |
(10,558) |
7,229 |
|
21% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-12-04 |
4 |
OE |
$8.02 |
$84,675 |
D/D |
10,558 |
17,787 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-12-03 |
4 |
AS |
$146.94 |
$2,962,751 |
D/D |
(20,163) |
7,229 |
|
21% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-12-03 |
4 |
OE |
$8.02 |
$161,707 |
D/D |
20,163 |
27,392 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-12-02 |
4 |
AS |
$144.59 |
$7,121,347 |
D/D |
(49,252) |
7,229 |
|
26% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-12-02 |
4 |
OE |
$8.02 |
$395,001 |
D/D |
49,252 |
56,481 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-11-05 |
4 |
AS |
$134.49 |
$2,928,520 |
D/D |
(21,775) |
7,229 |
|
32% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-11-05 |
4 |
OE |
$8.02 |
$174,636 |
D/D |
21,775 |
29,004 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-11-04 |
4 |
AS |
$133.79 |
$6,750,910 |
D/D |
(50,459) |
7,229 |
|
32% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-11-04 |
4 |
OE |
$8.02 |
$404,681 |
D/D |
50,459 |
57,688 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-11-03 |
4 |
AS |
$132.34 |
$12,136,240 |
D/D |
(91,705) |
7,229 |
|
32% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-11-03 |
4 |
OE |
$8.02 |
$735,474 |
D/D |
91,705 |
98,934 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-10-08 |
4 |
AS |
$118.84 |
$1,518,062 |
D/D |
(12,774) |
7,229 |
|
51% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-10-08 |
4 |
OE |
$8.02 |
$102,447 |
D/D |
12,774 |
20,003 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-10-07 |
4 |
AS |
$118.77 |
$1,590,330 |
D/D |
(13,390) |
7,229 |
|
51% |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-10-07 |
4 |
OE |
$8.02 |
$107,388 |
D/D |
13,390 |
20,619 |
|
- |
|
Tabuteau Herriot |
Chief Executive Officer |
|
2025-10-06 |
4 |
AS |
$120.17 |
$2,309,667 |
D/D |
(19,220) |
7,229 |
|
49% |
|
110 Records found
|
|
Page 1 of 5 |
|
|